GlaxoSmithKline PLC
25 April 2002
Director's Interests
I give below details of changes in interests in the Ordinary Share ADRs of
GlaxoSmithKline plc in respect of the under-mentioned director:-
Dr J P Garnier The Administrators of the SmithKline Beecham Mid-Term Incentive Plan
notified the Company and Dr Garnier on 24 April 2002 that he had
increased his interest by 819.244 Ordinary Share ADRs at a price of
$47.510 per Ordinary Share ADR following the re-investment of the
dividend paid to shareholders on 18 April 2002.
S M Bicknell
Company Secretary
25 April 2002
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.